Circadian Therapeutics and Arquimea Collaboration
Circadian Therapeutics and ARQUIMEA sign a collaboration agreement for the development of casein kinase 1 inhibitors for the treatment of diseases affecting the nervous system
- Co-development of molecules as an innovative treatment for nervous system diseases such as ALS, Parkinson’s or Alzheimer’s disease.
- Lead molecule, AP-2, is able to cross the blood-brain barrier and act directly on the brain with an innovative mechanism of action.
- The agreement will increase the chances of success, making more efficient progress in the treatment of several neurodegenerative diseases for which there is still no cure.